Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients-Reference-Cited by-同舟云学术

Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients

Published:2019-09-18 Issue:6 Volume:21 Page:
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Aryal Shambhu¹^ORCID,Katugaha Shalika B.¹²,Cochrane Adam¹³,Brown Anne Whitney¹,Nathan Steven D.¹,Shlobin Oksana A.¹,Ahmad Kareem¹,Marinak Lauren¹,Chun Jessica¹,Fregoso Margaret¹,Desai Shashank³,King Christopher¹

Affiliation:

1. Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia

2. Infectious Diseases Physicians, Inc. Falls Church Virginia

3. Advanced Heart Failure and Cardiac Transplant Program Inova Fairfax Hospital Falls Church Virginia

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13166

Reference9 articles.

1. Letermovir for the management of cytomegalovirus infection

2. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study

3. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

4. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review;JHLT Open;2024-11

2. Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients;Transplant Infectious Disease;2024-07-09

3. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients;Transplant Infectious Disease;2024-05-14

4. A call for cytomegalovirus stewardship initiatives in cardiothoracic transplant;JHLT Open;2024-05

5. Real‐life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients;Clinical Transplantation;2024-04-30